Publications
448 results found
Yen C, Dent PC, Noor R, et al., 2016, Roles of Tumor Characteristics in the Sub-Type Directed Management of Gastric Neuroendocrine Neoplasms, 57th Annual Meeting and Residents Fellow Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / 52nd Annual Meeting on Digestive Disease Week (DDW) / Meeting of the American-Gastroenterological-Association (AGA), Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S303-S303, ISSN: 0016-5085
Clift AK, Faiz O, Al-Nahhas A, et al., 2016, Role of Staging in Patients with Small Intestinal Neuroendocrine Tumours, Journal of Gastrointestinal Surgery, Vol: 20, Pages: 180-188, ISSN: 1873-4626
Small bowel neuroendocrine tumours are the commonest malignancy arising in the small intestine and have substantiallyincreased in incidence in recent decades. Patients with small bowel neuroendocrine tumours commonly develop lymphnode and/or distant metastases. Here, we examine the role of staging in 84 surgically treated patients with small bowel neuroendocrinetumours, comparing diagnostic information yielded from morphological, functional and endoscopic modalities. Furthermore,we correlate pre-operative staging with intra-operative findings in a sub-cohort of 20 patients. The vast majority ofpatients had been histologically confirmed to have low-grade (Ki-67 <2 %) disease; however, lymph node and distant metastaseswere observed in 74 (88.1 %) and 51 (60.7 %) of patients at presentation, respectively. Liver metastases were evident in 48(57.1 %) patients, with solely peritoneal and bone metastases observed in 2 (2.4 %) and 1 (1.2 %) patients, respectively. Fortypatients (47.6 %) received multimodal treatment. In our sub-cohort analysis, pre-operative imaging understaged disease in 14/20(70 %) when compared with intra-operative findings. In patients with multifocal primary tumours and miliary liver metastases, noimaging modality was able to detect entire disease spread. Overall, presently available imaging modalities heavily underestimatedisease stage, with meticulous intra-operative abdominal examination being superior to any imaging technology. Multimodaltreatment has an important role in prolonging survival.
Dubash S, Keat N, Mapelli P, et al., 2016, Biodistribution and Radiation Dosimetry of a Novel 18F-Fluoroethyl Triazole [Tyr3] Octreotate Analogue for PET Imaging Patients with Advanced Neuroendocrine Tumours, 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Publisher: KARGER, Pages: 58-58, ISSN: 0028-3835
Clift A, Giele H, Vrakas G, et al., 2016, Multivisceral Transplantation and Vascularised Sentinel Forearm Flap for a Metastatic Gut-Derived Neuroendocrine Tumour: Follow-Up, 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Publisher: KARGER, Pages: 107-107, ISSN: 0028-3835
Clift A, Pai M, Habib N, et al., 2016, Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Neoplasms, 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Publisher: KARGER, Pages: 91-91, ISSN: 0028-3835
Clift A, Faiz O, Al-Nahhas A, et al., 2016, Staging in Small Bowel Neuroendocrine Tumours: Roles and Shortcomings, 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Publisher: KARGER, Pages: 55-56, ISSN: 0028-3835
Malczewska A, Vlavianos P, Faiz O, et al., 2016, MEN1-Related Glucagonomatosis Incidentally Revealed during Management of Recurrent Intestinal Obstruction Following Surgery for Crohn's Disease, 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Publisher: KARGER, Pages: 111-111, ISSN: 0028-3835
Modlin IM, Frilling A, Salem RR, et al., 2015, Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies, Surgery, Vol: 159, Pages: 336-347, ISSN: 1532-7361
BackgroundSurgery is the only curative treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), but the prediction of residual disease/recurrence is limited in the absence of optimal biomarkers. We examined whether a blood-based multianalyte neuroendocrine gene transcript assay (NETest) would define tumor cytoreduction and therapeutic efficacy.MethodsThe NETest is a polymerase chain reaction–based analysis of 51 genes. Disease activity is scaled 0–100%; minimal <14%, low 14–47%, and high >47%. A total of 35 GEP-NETs in 2 groups were evaluated. I: after surgery (R0, n = 15; residual, n = 12); II: nonsurgery (n = 8: embolization with gel-foam alone [bland: n = 3]), transarterial chemoembolization (n = 2), and radiofrequency embolization (n = 3). Measurement (quantitative real-time-polymerase chain reaction) and chromogranin A (CgA; enzyme-linked immunosorbent assay) were undertaken preoperatively and 1 month after treatment.ResultsNETest score was increased in 35 (100%) preoperatively; 14 (40%) had increased CgA (χ2 = 30, P < 2 × 10−8). Resection reduced NETest from 80 ± 5% to 29% ± 5, (P < .0001). CgA decrease was insignificant (14.3 ± 1.6U/L to 12.2 ± 1.7U/L). NETest decreases correlated with diminished tumor volume (R2 = 0.29, P = .03). Cytoreduction significantly reduced NETest from 82 ± 3% to 41% ± 6, P < .0001). CgA was not decreased (21.4 ± 5.5U/L to 18.4 ± 10.1U/L). Four (36%) of 11 R0s with increased NETest at 1 month developed positive imaging (sensitivity 100%, specificity 20%). One hundred percent (ablated group) were transcript- and image-positive.ConclusionBlood NET transcripts delineate surgical resection/cytoreduction and facilitate identification of residual disease.Neuroendocrine tumors (nets) are diverse tumors considered previously as “carcinoids.”1 The lesions are ubiquitous in location but are especially common within
Fischer MA, Raptis DA, Donati OF, et al., 2015, MR imaging features for improved diagnosis of hepatocellular carcinoma in the non-cirrhotic liver: Multi-center evaluation, EUROPEAN JOURNAL OF RADIOLOGY, Vol: 84, Pages: 1879-1887, ISSN: 0720-048X
- Author Web Link
- Cite
- Citations: 19
Oberg K, Modlin IM, De Herder W, et al., 2015, Consensus on biomarkers for neuroendocrine tumour disease, Lancet Oncology, Vol: 16, Pages: e435-e446, ISSN: 1474-5488
Roedel C, Graeven U, Fietkau R, et al., 2015, Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial, Lancet Oncology, Vol: 16, Pages: 979-989, ISSN: 1470-2045
Miller HC, Kidd M, Castellano L, et al., 2015, Molecular genetic findings in small bowel neuroendocrine neoplasms: a review of the literature, INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, Vol: 2, Pages: 143-150, ISSN: 2045-0869
- Author Web Link
- Cite
- Citations: 1
Miller HC, Kidd M, Modlin IM, et al., 2015, Glucagon receptor gene mutations with hyperglucagonemia but without the glucagonoma syndrome, World Journal of Gastrointestinal Surgery, Vol: 7, Pages: 60-66, ISSN: 1948-9366
Pancreatic neoplasms producing exclusively glucagon associated with glucagon cell hyperplasia of the islets and not related to hereditary endocrine syndromes have been recently described. They represent a novel entity within the panel of non-syndromic disorders associated with hyperglucagonemia. This case report describes a 36-year-old female with a 10 years history of non-specific abdominal pain. No underlying cause was evident despite extensive diagnostic work-up. More recently she was diagnosed with gall bladder stones. Abdominal ultrasound, computerised tomography and magnetic resonance imaging revealed no pathologic findings apart from cholelithiasis. Endoscopic ultrasound revealed a 5.5 mm pancreatic lesion. Fine needle aspiration showed cells focally expressing chromogranin, suggestive but not diagnostic of a low grade neuroendocrine tumor. OctreoScan(®) was negative. Serum glucagon was elevated to 66 pmol/L (normal: 0-50 pmol/L). Other gut hormones, chromogranin A and chromogranin B were normal. Cholecystectomy and enucleation of the pancreatic lesion were undertaken. Postoperatively, abdominal symptoms resolved and serum glucagon dropped to 7 pmol/L. Although H and E staining confirmed normal pancreatic tissue, immunohistochemistry was initially thought to be suggestive of alpha cell hyperplasia. A count of glucagon positive cells from 5 islets, compared to 5 islets from 5 normal pancreata indicated that islet size and glucagon cell ratios were increased, however still within the wide range of normal physiological findings. Glucagon receptor gene (GCGR) sequencing revealed a heterozygous deletion, K349_G359del and 4 missense mutations. This case may potentially represent a progenitor stage of glucagon cell adenomatosis with hyperglucagonemia in the absence of glucagonoma syndrome. The identification of novel GCGR mutations suggests that these may represent the underlying cause of this condition.
Frilling A, Clift AK, 2015, Therapeutic Strategies for Neuroendocrine Liver Metastases, CANCER, Vol: 121, Pages: 1172-1186, ISSN: 0008-543X
- Author Web Link
- Cite
- Citations: 115
Frilling A, Giele H, Vrakas G, et al., 2015, Modified Liver-free Multivisceral Transplantation for a Metastatic Small Bowel Neuroendocrine Tumor: A Case Report, TRANSPLANTATION PROCEEDINGS, Vol: 47, Pages: 858-862, ISSN: 0041-1345
- Author Web Link
- Cite
- Citations: 14
Frilling A, Clift AK, Faiz O, et al., 2015, Role of Preoperative Staging in Patients With Small Intestinal Neuroendocrine, 46th Annual Digestive Disease Week (DDW), Publisher: W B SAUNDERS CO-ELSEVIER INC, Pages: S1119-S1119, ISSN: 0016-5085
Harper S, Carroll RW, Frilling A, et al., 2015, Primary Lymph Node Gastrinoma: 2 Cases and a Review of the Literature, JOURNAL OF GASTROINTESTINAL SURGERY, Vol: 19, Pages: 651-655, ISSN: 1091-255X
- Author Web Link
- Cite
- Citations: 9
Kidd M, Alaimo D, Callahan S, et al., 2015, A Multi-Gene Transcript Blood Molecular Signature for Gut Neuroendocrine Tumors (NETs) Delineates Surgical Efficacy, PANCREAS, Vol: 44, Pages: 354-354, ISSN: 0885-3177
Tran K, Khan S, Taghizadehasl M, et al., 2015, Gallium-68 dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin, HELLENIC JOURNAL OF NUCLEAR MEDICINE, Vol: 18, Pages: 19-24, ISSN: 1790-5427
- Author Web Link
- Cite
- Citations: 29
Kidd MS, Modlin IM, Frilling A, et al., 2015, Neuroendocrine gene transcript analysis of blood to define the completeness of surgical resection and identify stable or progressive neuroendocrine tumor disease, Gastrointestinal Cancers Symposium, Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
Ramachandran R, Bech P, Murphy KG, et al., 2015, Comparison of the Utility of Cocaine- and Amphetamine-Regulated Transcript (CART), Chromogranin A, and Chromogranin B in Neuroendocrine Tumor Diagnosis and Assessment of Disease Progression, Journal of Clinical Endocrinology & Metabolism, Vol: 100, Pages: 1520-1528, ISSN: 1945-7197
Frilling A, Ebert M, 2015, Treatment of Non-Colorectal Liver Metastases, VISCERAL MEDICINE, Vol: 31, Pages: 386-386, ISSN: 2297-4725
- Author Web Link
- Cite
- Citations: 1
Fan ST, Le Treut YP, Mazzaferro V, et al., 2015, Liver transplantation for neuroendocrine tumour liver metastases, HPB, Vol: 17, Pages: 23-28, ISSN: 1365-182X
- Author Web Link
- Cite
- Citations: 52
Clift A, Giele H, Vrakas G, et al., 2015, A Novel Approach for a Metastatic Gut-Derived Neuroendocrine Tumour: Simultaenous Intestinal and Vascularised Sentinel Forearm Flap Transplantation, 12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Publisher: KARGER, Pages: 149-149, ISSN: 0028-3835
Clift AK, Drymousis P, Al-Nahhas A, et al., 2015, Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours, NEUROENDOCRINOLOGY, Vol: 102, Pages: 26-32, ISSN: 0028-3835
- Author Web Link
- Cite
- Citations: 28
Frilling A, Al-Nahhas A, Clift AK, 2015, Transplantation and Debulking Procedures for Neuroendocrine Tumors, NEUROENDOCRINE TUMORS: A MULTIDISCIPLINARY APPROACH, Vol: 44, Pages: 164-176, ISSN: 0301-3073
- Author Web Link
- Cite
- Citations: 9
Clift A, Drymousis P, Al-Nahhas A, et al., 2015, Second Primary Malignancies in Patients with Neuroendocrine Tumors, 12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Publisher: KARGER, Pages: 149-149, ISSN: 0028-3835
Clift A, Frilling A, Smith G, et al., 2014, Video capsule endoscopy for detecting primary tumour site in patients with metastatic neuroendocrine tumours, Annual Meeting of the Association-of-Upper-Gastrointestinal-Surgeons-of-Great-Britain-and-Ireland, Publisher: WILEY-BLACKWELL, Pages: 37-38, ISSN: 0007-1323
Frilling A, Smith G, Clift AK, et al., 2014, Capsule endoscopy to detect primary tumour site in metastatic neuroendocrine tumours, DIGESTIVE AND LIVER DISEASE, Vol: 46, Pages: 1038-1042, ISSN: 1590-8658
- Author Web Link
- Cite
- Citations: 26
Miller H, Castellano L, Frampton A, et al., 2014, 1158PROLE OF MICRORNA AS BIOMARKERS IN SMALL BOWEL NEUROENDOCRINE TUMOURS., Ann Oncol, Vol: 25
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.